SC0191 / WuXi AppTec, Shijiazhuang Sagacity, Wuxi Biocity - LARVOL DELTA

WEE1 as a therapeutic target in TP53 and ARID1A concurrent mutant colorectal cancers (AACR 2025) - P2 | "Notably, ARID1A knockout sensitizes TP53-mutant, but not TP53-wildtype CRC cell lines, to WEE1 inhibitor MK-1775 or ZN-c3...These studies paralleled a phase 1b/2 clinical trial with SC0191 (a novel WEE1 inhibitor) based combination therapy in a cohort of late-line metastatic CRC patients (NCT06363552)...In conclusion, our research showed that targeting WEE1 is effective in TP53 and ARID1A mutant colorectal cancers. This therapeutic strategy is being tested in a phase 2 study for mCRC patients."

Colorectal Cancer • Oncology • Solid Tumor • ARID1A • TP53 • WEE1

A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer (clinicaltrials.gov) - P2 | N=36 | Not yet recruiting | Sponsor: Tianshu Liu

Combination therapy • Metastases • New P2 trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer (clinicaltrials.gov) - P1/2 | N=112 | Not yet recruiting | Sponsor: Biocity Biopharmaceutics Co., Ltd.

Metastases • New P1/2 trial • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor

[VIRTUAL] Preclinical evaluation of SC0191, a small molecule inhibitor of Wee1 kinase. (ASCO 2020) - "Moreover, SC0191 oral administration showed significant antitumor efficacy which was better than AZD1775, in the NCI-H446 and BxPC-3 CDX mouse models, respectively. A novel Wee1 inhibitor, SC0191, has demonstrated excellent antitumor efficacy in TP53 mutant solid cancer preclinical studies, and represents a promising clinical candidate for treating solid tumors, such as SCLC and PC. Research Funding: Sagacity"

Preclinical • Gastrointestinal Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Small Cell Lung Cancer • Solid Tumor • Thoracic Cancer • CDK1 • TP53